Tr1X
The Director/Senior Director, Program Management provides strategic leadership and hands-on operational support for cell therapy programs in autoimmune indications. This role aligns cross-functional teams, manages risks and dependencies, and drives the execution of complex preclinical and clinical programs from early development through registrational studies. The position partners closely with Clinical Development, Regulatory, Technical Operations, and R&D to ensure programs deliver against milestones and organizational objectives.
Tr1X is a clinical-stage biotechnology company engineering a novel class of regulatory T cell-based therapies to cure autoimmune and inflammatory diseases. Leveraging cutting-edge genetic engineering and deep immunology expertise, Tr1X develops allogeneic, off-the-shelf Tr1/Treg cell therapies designed to restore immune tolerance and reset the immune system. The company has four active clinical programs spanning Crohn's disease, multiple sclerosis, graft-versus-host disease prevention following stem cell transplant, and autoimmune uveitis.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Tr1X.
Senior Manager, Program Management
CRISPR Therapeutics
Medical Director
Orca Bio
Principal Scientist, Cell Therapy Translational Biology Research
Bristol Myers Squibb
Senior Scientist, Immunology
MSD
R&D Manager Leadership Development Program, Solid Tumor
Legend Biotech
Global Commercial Director, Immunology Cell Therapy
AstraZeneca